Trelegy Ellipta filing accepted by EMA for asthma
As it stands there is no single inhaled triple therapy available for the treatment of asthma in Europe.
Read More
Tag: Ellipta
Vectura wins patent litigation battle against GSK, awarded $89.7M
The companies had entered into an agreement in 2010 under which GSK had taken a license to formulation technology covered by a Vectura patent family.
Read More
Hikma, Vectura to develop generic rivals to GSK’s Ellipta portfolio
Hikma Pharmaceuticals and Vectura have signed a deal to develop and market generic versions of GlaxoSmithKline’s Ellipta portfolio, utilising the latter’s Open-Inhale-Close dry powder inhaler device.
Read More
GSK happy with 3 percent rise in 2017 sales
GlaxoSmithKline has reported a sales hike of 3 percent at constant exchange rates (CER*) for 2017, after growth was recorded across all of its three global businesses.
Read More
